Advertisement

American Journal of Cardiovascular Drugs

, Volume 16, Issue 1, pp 55–65 | Cite as

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

  • Stephen J. NichollsEmail author
  • Rishi Puri
  • Kathy Wolski
  • Christie M. Ballantyne
  • Philip J. Barter
  • H. Bryan Brewer
  • John J. P. Kastelein
  • Bo Hu
  • Kiyoko Uno
  • Yu Kataoka
  • Jean-Paul R. Herrman
  • Bela Merkely
  • Marilyn Borgman
  • Steven E. Nissen
Original Research Article

Abstract

Background

Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown.

Methods

ASSURE was a double-blind, randomized, multicenter trial in which 323 patients with angiographic coronary disease and low high-density lipoprotein cholesterol (HDL-C) levels were randomized in a 3:1 fashion to treatment with the BET protein inhibitor RVX-208 200 mg or placebo for 26 weeks. Plaque progression was measured with serial intravascular ultrasound imaging. Lipid levels, safety, and tolerability were also assessed.

Results

During treatment, apolipoprotein (apo)A-I increased by 10.6 % with placebo (P < 0.001 compared with baseline) and 12.8 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.18. HDL-C increased by 9.1 % with placebo (P < 0.001 compared with baseline) and 11.1 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.24. Low-density lipoprotein cholesterol (LDL-C) decreased by 17.9 % with placebo (P < 0.001 compared with baseline) and 15.8 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.55. The primary endpoint, the change in percent atheroma volume, decreased 0.30 % in placebo-treated patients (P = 0.23 compared with baseline) and 0.40 % in the RVX-208 group (P = 0.08 compared with baseline), between groups P = 0.81. Total atheroma volume decreased 3.8 mm3 in the placebo group (P = 0.01 compared with baseline) and 4.2 mm3 in the RVX-208 group (P < 0.001 compared with baseline), P = 0.86 between groups. A greater incidence of elevated liver enzymes was observed in RVX-208-treated patients (7.1 vs. 0 %, P = 0.009).

Conclusion

Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo.

Trial Registration

ClinicalTrials.gov identifier—NCT01067820.

Keywords

Atorvastatin Rosuvastatin Plaque Burden Interactive Voice Response Incremental Benefit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Data Safety Monitoring Board: Peter Ganz (Chair), Eva Lonn, Gregory Schwartz, Danielle Brennan.

Intravascular Ultrasound Core Laboratory Staff: William Magyar, Jordan Andrews, Eva Balazs, Anne Colagiovanni, Teresa Fonk, Karilane King, Erin Mayock, Roman Poliszczuk, Rhiannon Regal, Jill Rusticelli.

Additional contributions: We thank Craig Balog, BS, C5Research statistical support. Helen Street and Kim Nguyen at Resverlogix and Deirdre Albertson and Alla Sharorodskaya at inVentiv for their role in study coordination.

Investigators: Argentina: Sanatorio Allende Hipolito, Córdoba (E. Moreyra, MD), Hospital Privado, Córdoba (M. Ballarino, MD), Instituto de Cardiología de Corrientes, Corrientes Capital (J. Baccaro, MD), Sanatorio Parque S. A. Privado,Córdoba (H. Luquez, MD), Instituto de diagnóstico y tratamiento de afecciones cardiovasculares, La Plata (D. Grinfeld, MD), ICBA Instituto Cardiovascular de Buenos Aires, Ciudad de Buenos Aires (L. Padilla, MD), Instituto DAMIC SRL, Córdoba (A. Lorenzatti, MD), Sanatorio San Lucas, San Isidro (G. Marchetti, MD), Clinica Chutro SRL, Córdoba (H. Jure, MD), Sanatorio Güemes,Ciudad de Buenos Aires (M. Bettinotti, MD); Belgium: Universitair Ziekenhuis Antwerpen, Edegem (C. Vrints, MD), Ziekenhuis Oost Limburg, Genk (M. Vrolix, MD), Universite Catholique de Louvain, Brussels (J. Renkin, MD), Centre Hospitalier Universitaire de Charleroi, Charleroi (J. Lalmand, MD); Brazil: Instituto do Coração do Triângulo Mineiro, Uberlândia (R. Vieira Botelho, MD), Hospital Cardiológico Costantini, Curitiba (Costantino Roberto Costantini Frack, MD), Instituto do Coração, São Paulo (P. Lemos, MD), Santa Casa de Misericórdia de Porto Alegre, Porto Alegre (V. Correia deLima, MD), Hemodinâmica Meridional, Cariacica (B. Moulin Machado, MD), Centro de Pesquisa em Cardiologia da Via Médica, Goiânia (W. Kunz Sebba Barroso de Souza, MD), Hospital do Coração do Brasil, Brasília (A. Gomes Taques Fonseca, MD), Instituto Dante Pazzanese de Cardiologia, São Paulo (J. de Ribamar Costa Junior, MD); Hungary: Szent-Györgyi Albert Klinikai Központ, Szeged (I. Ungi, MD), Semmelweis Egyetem Kardiológiai Közpon, Budapest (B. Merkely, MD), Pécsi Tudományegyetem, Pécs (I. Horvath, MD), Fővárosi Önkormányzat Bajcsy-Zsilinszky Kórház, Budapest (B. Nagybaczoni, MD), Honvédkórház - Állami Egészségügyi Központ, Budapest (R. Kiss, MD), Budai Irgalmasrendi Kórhá, Budapest (A. Zsoldos, MD); Netherlands: Onze Lieve Vrouwe Gasthuis, Amsterdam, (J. P. Herrman, MD), Isala Klinieken, Zwolle (M. Gosselink, MD), St. Antonius Ziekenhuis, Niewegein (B. Rensing, MD), Catharina Ziekenhuis, Eindhoven (C. Joost Botman, MD), Maasstad Ziekenhuis, Rotterdam (P. Smits, MD), Maastricht Universitair Medisch Centrum, Maastricht (A. Moens, MD), Canisius Wilhelmina Ziekenhuis, Nijmegen (A. J. M. Oude Ophuis, MD), Medisch Spectrum Twente, Enschede (C. Von Birgelen, MD), Medisch Centrum Alkmaar, Alkmaar (A. A. C. M. Heestermans, MD); Poland: Samodzielna Pracownia Hemodynamiki, Krakow (D. Dudek, MD), Klinika Kardiologii Inwazyjnej, Warszawa (R. Gil, MD), Zakład Kardiologii Inwazyjnej, Katowice (A. Ochala, MD), Oddział Strukturalnych Chorób Serca Samodzielny Publiczny Szpital Kliniczny, Katowice (G. Smolka, MD), Instytut Kardiologii, Warszawa (A. Witkowski, MD); Russia: Acad. V. I. Shumakov, Moscow (V. Chestukhin, MD), St. Petersburg State Healthcare Institution, Saint Petersburg (L. Shcheglova, MD),

Russian Cardiology Research-and-Production Complex, Moscow (V. Kukharchuk MD, M. Ruda, MD, and F. Ageev, MD), 3 Central Military Clinical Hospital, Moscow (V. Ivanov, MD), Tyumen Department of South-Ural Scientific Center of RAMS, Tyumen (S. Shalaev, MD), A. N. Bakulev of RAMS Cardiosurgery Institution, Moscow (S. Matskeplishvili, MD), Scientific Research Cardiology Institute of Sibirian Branch of RAMS,Tomsk (O. Koshelskaya, MD), FSI Federal Center of Heart, Blood and Endocrinology, St. Petersburg (M. Karpenko, MD), FSI State Scientific Research Center of Preventive Medicine of Rosmedtechnologies, Moscow (V. Mazaev, MD), Orenburg State Medical Academy of Roszdrav, Orenburg (R. Sayfutdinov, MD); Spain: Hospital de Meixoeiro, Vigo (A. Iniguez, MD), Hospital Clinico Universitario Virgen de la Victoria, Málaga (J. Maria Hernandez, MD), Hospital de Cabueñes, Gijón (J. Rondan, MD), Hospital Universitari Germans Trias i Pujol, Barcelona (J. Mauri, MD), Hospital Universitario La Paz, Madrid (R. Moreno, MD), Hospital de Galdakao-Usansolo, Galdakao (J. Ramon Rumoroso, MD), Hospital General Universitario Santa Lucia, Cartagena (F. Pico, MD), Hospital Universitari de Bellvitge, Barcelona (A. Cequier, MD), Hospital Clinico Universitario San Carlos, Madrid (F. Alfonso, MD), Hospital Clínico Universitario de Santiago, Santiago de Compostela (R. Trillo, MD), Hospital Vall d’Hebrón, Barcelona (B. Blanco, MD), Hospital Universitario Marqués de Valdecilla, Santander (J. Zueco, MD).

Author contributions

Drs. Nicholls and Nissen and the Cleveland Clinic Coordinating Center for Clinical Research had full and independent access to all of the data in the study. Dr. Nicholls takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Nicholls and Nissen and Ms. Wolski and Borgman were responsible for study concept and design. Drs. Nicholls, Puri, Uno, Herrman, Merkely, and Kataoka and Ms. Borgman take responsibility for data acquisition. Drs. Nicholls, Nissen, Ballantyne, Barter, Brewer, Kastelein, Puri, Uno, Kataoka, Hu, Herrman, and Merkely and Ms. Wolski and Ms. Borgman analysed and interpreted the data. Drs. Nicholls and Nissen and Ms. Wolski drafted the manuscript. Drs. Nicholls, Nissen, Ballantyne, Barter, Brewer, Kastelein, Puri, Uno, Kataoka, Hu, Herrman, and Merkely and Ms. Wolski and Ms. Borgman provided critical revision of the manuscript for important intellectual content. For the purpose of the academic interpretation of the study, Ms. Wolski and Dr. Hu performed all primary statistical analyses of the study that were used for the manuscript. Ms. Wolski is an employee of the Cleveland Clinic Coordinating Center for Clinical Research. Dr. Hu is a faculty member within the Department of Quantitative Health Sciences at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Drs. Nicholls and Nissen obtained funding for the study. Ms. Borgman provided administrative support.

Compliance with Ethical Standards

Financial support

The study was funded by Resverlogix Corporation.

Role of the Sponsor

The sponsor, Resverlogix Corporation, participated actively in designing the study, developing the protocol, and providing logistical support during the trial. Monitoring of the study was performed by a contract research organization, inVentiv Health Inc., under contract with the sponsor. The sponsor maintained the trial database. Statistical analysis was performed by statisticians employed by inVentiv, although the analysis employed by the manuscript represent those performed by the academic statisticians (Ms. Wolski, Dr. Hu). After completion of the trial, as specified in the study contract, a complete copy of the database was transferred to the Cleveland Clinic Coordinating Center for Clinical Research, where analyses were verified by independent statisticians, Kathy Wolski, MPH and Bo Hu, PhD. The manuscript was prepared by the corresponding author and modified after consultation with co-authors. The sponsor was permitted to review the manuscript and suggest changes, but the final decision on content was exclusively retained by the academic authors.

Financial disclosures

The study was sponsored by Resverlogix Corporation. SJN reports receiving research support from AstraZeneca, Novartis, Eli Lilly, Anthera, LipoScience, Roche, and Resverlogix and has received honoraria or been a consultant for AstraZeneca, Roche, Esperion, Abbott, Pfizer, Merck, Takeda, LipoScience, Omthera, Novo-Nordisk, Sanofi-Aventis, Atheronova, Anthera, CSL Behring, and Boehringer. HBB is a consultant for Merck, AstraZeneca, Eli Lilly, Roche, Amgen, and Sanofi. CMB has received research support from Abbott, Amarin, Amgen, Eli Lilly, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo, Takeda, the National Institutes of Health, and the American Heart Association, is a consultant for Abbott, Aegerion, Amarin, Amgen, Arena, Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck, Novartis, Omthera, Pfizer, Resverlogix, Regeneron, Roche, and Sanofi-Synthelabo and serves on the speaker’s bureau for Abbott. PJB has received research grants from Merck and Pfizer, received honoraria from Amgen, AstraZeneca, ISIS, Kowa, Merck, Novartis, Pfizer, and Roche and serves on advisory boards for AstraZeneca, CSL Behring, Kowa, Eli Lilly, Merck, Novartis, Pfizer, and Roche. JJPK has received research support from the Dutch Heart Foundation (2010T082) and has received honoraria or has been a consultant for AstraZeneca, Novartis, Eli Lilly, Anthera, Roche, Resverlogix, Pfizer, Merck, Omthera, Sanofi-Aventis, Regeneron, Amgen, AtheroNova, CSL Behring, Boehringer Ingelheim, Aegerion, the Medicines Company, Isis Pharmaceuticals, Genzyme, Amarin, Xenon Pharma, Servier, and Cerenis. SEN has received research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis. He has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees, or any other payments from any for-profit entity are paid directly to charity, so that neither income nor any tax deduction is received. No assistance in the preparation of this article is to be declared. RP, KU, YK, MB, JRH, BM, BH, and KW have no potential conflicts to disclose.

References

  1. 1.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease.The Framingham Study. Am J Med. 1977;62:707–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455–61.PubMedGoogle Scholar
  3. 3.
    AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.Google Scholar
  4. 4.
    Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.PubMedCrossRefGoogle Scholar
  5. 5.
    HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.Google Scholar
  6. 6.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedCrossRefGoogle Scholar
  7. 7.
    Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299:1547–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Nicholls SJ, Gordon A, Johannson J, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Schoenhagen P, Sapp SK, Tuzcu EM, et al. Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration. J Am Soc Echocardiogr. 2003;16:277–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–76.PubMedCrossRefGoogle Scholar
  23. 23.
    Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55:2399–407.PubMedCrossRefGoogle Scholar
  24. 24.
    Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51:314–24.PubMedCrossRefGoogle Scholar
  25. 25.
  26. 26.
    Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078–87.PubMedCrossRefGoogle Scholar
  27. 27.
    Puri R, Nissen SE, Ballantyne CM, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013;34:1818–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Banach M, Rizzo M, Toth PP, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci AMS. 2015;11:1–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Stephen J. Nicholls
    • 1
    Email author
  • Rishi Puri
    • 2
  • Kathy Wolski
    • 2
  • Christie M. Ballantyne
    • 3
  • Philip J. Barter
    • 4
  • H. Bryan Brewer
    • 5
  • John J. P. Kastelein
    • 6
  • Bo Hu
    • 2
  • Kiyoko Uno
    • 2
  • Yu Kataoka
    • 1
  • Jean-Paul R. Herrman
    • 7
  • Bela Merkely
    • 8
  • Marilyn Borgman
    • 2
  • Steven E. Nissen
    • 2
  1. 1.South Australian Health and Medical Research InstituteAdelaideAustralia
  2. 2.Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical ResearchCleveland ClinicClevelandUSA
  3. 3.Section of Cardiovascular ResearchBaylor College of Medicine and the Methodist DeBakey Heart and Vascular CenterHoustonUSA
  4. 4.University of New South WalesSydneyAustralia
  5. 5.Medstar Research InstituteHyattsvilleUSA
  6. 6.Department of Vascular Medicine, Academic Medical CenterUniversity of MedicineAmsterdamThe Netherlands
  7. 7.Department of CardiologyOnze Lieve Vrouwe GasthuisAmsterdamThe Netherlands
  8. 8.Heart and Vascular CenterSemmelweis UniversityBudapestHungary

Personalised recommendations